 BASKING RIDGE, N.J., Sept. 08, 2021 GLOBE NEWSWIRE -- Caladrius Biosciences, Inc. Nasdaq: CLBS Caladrius or the Company, a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, President and CEO of Caladrius, will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021. 